Publication Date
12-5-2023
Journal
BMC Pulmonary Medicine
Abstract
PURPOSE: This study aimed to evaluate the efficacy and safety of montelukast (Mon) + fluticasone propionate (Flu) versus Flu in the treatment of cough variant asthma (CVA) in children.
METHODS: Eligible documents were selected from various databases. Weighted mean difference (WMD) and 95% confidence interval (CI) were used to evaluate continuous variables, and categorical variables were evaluated using risk ratio (RR) and 95% CI. Heterogeneity analysis was performed using Cochran's Q test and I
RESULTS: Nine studies were included, and Flu + Mon was found to significantly improve the total effective rate and reduce cough recurrence compared to Flu. The cough remission and disappearance times in the Mon + Flu group were significantly lower than those in the Flu group. FEV1% recovery in the Mon + Flu group was significantly better than that in the Flu group.
CONCLUSION: Mon + Flu is effective and safe for the treatment of CVA in children.
Keywords
Child, Humans, Acetates, Anti-Asthmatic Agents, Asthma, Cough, Cyclopropanes, Fluticasone, Quinolines
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Medical Microbiology Commons, Medical Pathology Commons, Pulmonology Commons
Comments
Supplementary Materials
PMID: 38053076